Brief Description
Developer of next-generation gene editing therapeutics in a preclinical pipeline. The company creates programmable nucleases that selectively target and edit specific cell populations directly in the body. These engineered nucleases will enable direct intervention in vivo like a true administered biologic. Spotlight Therapeutics co-founders include Dr. Patrick Hsu, a UC Berkeley Assistant Professor of Bioengineering and co-founder of the Arc Institute.
Timeline
- 2017. Company founded.
Inventors
Colleen McGourty, Lorena de Onate, Ross Wilson